Our lead product, CTx001, is in pre-clinical development for the localised treatment of Geographic Atrophy (‘dry’ age-related macular degeneration). In addition, we are developing therapeutics that are aimed at systemic modulation of the complement system.
We anticipate that these assets will meet the needs of a wide range of patients with complement-mediated disease.